NDAORALTABLET
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Started Feb 2026
25 enrolled
Metastatic Renal Cell CarcinomaMetastatic Renal CancerRenal Cell Carcinoma+3 more
Avelumab, Palbociclib and Axitinib in Advanced RCC
Started May 2024
0Advanced Clear Cell Renal Cell Carcinoma
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Started Apr 2024
5 enrolled
Advanced Solid Tumors
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Started Apr 2023
199 enrolled
Renal Cell Carcinoma
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Started Apr 2023
298 enrolled
Renal Cell CarcinomaNeoadjuvant
Loss of Exclusivity
LOE Date
Jul 12, 2037
138 months away
Patent Expiry
Jul 12, 2037
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8791140 | Dec 14, 2030 | Substance | — |
| 8791140*PED | Jun 14, 2031 | — | |
| 12534530 | Feb 3, 2035 | U-4412 | |
| 10570202 | Feb 3, 2035 | U-2844 | |
| 10570202*PED | Aug 3, 2035 | — |